Clinical Trial Update: GM-CSF Inhalation to Prevent ARDS in COVID-19 Pneumonia [Phase 2]

View source ↗

Summary

Phase 2 clinical trial assessing inhaled GM-CSF to prevent ARDS in patients with COVID-19 pneumonia has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• COVID-19 Pneumonia
• Respiratory Syndrome Pneumonia

Drugs mentioned

• GM-CSF inhalation (granulocyte-macrophage colony-stimulating factor)

Snippet

Sponsor: University of Giessen | Conditions: Severe Acute Respiratory Syndrome (SARS) Pneumonia, COVID-19 Pneumonia | Phase 2 | Status: COMPLETED